Injection drug use (IDU) is a major risk factor for hepatitis C virus (HCV), yet many are denied treatment with new direct-acting antivirals. In fact, researchers don’t normally include these HCV patients in their clinical trials.
However, recent findings from a multicountry study found that HCV patients being treated for opioid addiction achieved high rates of sustained virologic response (SVR) after 12 weeks of therapy with elbasvir-grazoprevir (Zepatier, Merck), compared with those